Abstract: Novel anti-NRPl antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 August 2007

For two-letter codes and other abbreviations, refer to the “Guidance Notes on Codes and Abbreviations” appearing at the beginning of each regular issue of the PCT Gazette.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>POZAS ESTHER ET AL: &quot;Age-dependent effects of secreted semaphorins 3A, 3F, and 3E on developing hippocampal axons: In vitro effects and phenotype of Semaphorin 3A (-/-) mice&quot; MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 18, no. 1, July 2001 (2001-07), pages 26-43, XP002435741 ISSN: 1044-7431 page 40, left-hand column, last paragraph ------ -/--</td>
<td></td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of Box C

D See patent family annex

Date of the actual completion of the international search

31 May 2007

Date of mailing of the international search report

15/06/2007

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016

Authorized officer

Kalsner, Inge
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>NASARRE PATRICK ET AL: &quot;Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading.&quot; NEOPLASIA (NEW YORK), vol. 5, no. 1, January 2003 (2003-01), pages 83-92, XP002435742 ISSN: 1522-8002 abstract</td>
<td>1, 2</td>
</tr>
<tr>
<td>X</td>
<td>TORDJMAN RAFAELE ET AL: &quot;A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response&quot; NATURE IMMUNOLOGY, vol. 3, no. 5, May 2002 (2002-05), pages 477-482, XP002435745 ISSN: 1529-2908 the whole document</td>
<td>1</td>
</tr>
<tr>
<td>A</td>
<td>GU CHENHUA ET AL: &quot;Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development.&quot; DEVELOPMENTAL CELL, vol. 5, no. 1, July 2003 (2003-07), pages 45-57, XP002435746 ISSN: 1534-5807 the whole document</td>
<td>1, 2, 4-10, 17-30</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
</tbody>
</table>
Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

1  [ ] Claims Nos because they relate to subject matter not required to be searched by this Authority, namely

2  [ ] Claims Nos because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically

3  [ ] Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows

see additional sheet

1  [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims

2  [X] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee

3  [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos

4  [D] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest

[ ] No protest accompanied the payment of additional search fees

Form PCT/ISA/21.0 (continuation of first sheet (2)) (January 2004)
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 2, 4-10 (compl.); 1, 17-30 (all part.)

   Anti-neuropilin-1 (NRP-I) antibody capable of inhibiting the interaction of NRP-I with semaphorin; use of the antibody in the manufacture of a medicament for treatment or prevention of a disorder associated with pathological angiogenesis

2. claims: 3, 11-16 (compl.); 1, 17-30

   Anti-neuropilin-1 (NRP-I) antibody capable of inhibiting the interaction of NRP-I with vascular endothelial growth factor (VEGF); use of the antibody in the manufacture of a medicament for treatment or prevention of a disorder associated with pathological angiogenesis